Trials / Recruiting
RecruitingNCT06771544
Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 14 (estimated)
- Sponsor
- University of California, Irvine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase 2, single-arm, open label clinical trial determining efficacy of Cyclophosphamide and Pembrolizumab in subjects with melanoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pembrolizumab | Given IV |
| DRUG | Cyclophosphamide | Given PO |
Timeline
- Start date
- 2024-12-23
- Primary completion
- 2027-12-01
- Completion
- 2028-12-01
- First posted
- 2025-01-13
- Last updated
- 2026-03-10
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06771544. Inclusion in this directory is not an endorsement.